Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis

Discussion
Higher levels of sGFAP correlated with subsequent progression, particularly in nonactive patients, whereas sNfL reflected acute disease activity in patients with MS at high risk of underlying progressive pathology. Thus, sGFAP and sNfL levels may be used to stratify patients with progressive MS for clinical research studies and clinical trials and may inform clinical care.

Source: Neurology Neuroimmunology and Neuroinflammation - November 14, 2022 Category: Neurology Authors: Barro, C., Healy, B. C., Liu, Y., Saxena, S., Paul, A., Polgar-Turcsanyi, M., Guttmann, C. R. G., Bakshi, R., Kropshofer, H., Weiner, H. L., Chitnis, T. Tags: Research Article Source Type: research